- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05155553
QIAstat-Dx® Meningitis/Encephalitis Panel Performance Evaluation Study
June 16, 2023 updated by: QIAGEN Gaithersburg, Inc
An Observational Clinical Performance Evaluation Study Testing Residual Specimens of Cerebrospinal Fluid Obtained by Lumbar Puncture From Meningitis/Encephalitis Subjects Using the QIAstat-Dx® Meningitis/Encephalitis Panel
Study for performance evaluation of the QIAstat-Dx® Meningitis/Encephalitis Panel in comparison with other chosen comparator methods.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This multicenter study aims to evaluate the performance of QIAstat-Dx Meningitis/Encephalitis (ME) Panel with another validated comparator method.
Study Type
Observational
Enrollment (Estimated)
1600
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Manchester, United Kingdom
- QIAGEN
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Subjects (adults and children) with signs and symptoms of meningitis and/or encephalitis
Description
Inclusion Criteria:
- Residual specimens (minimum 500μL) of CSF obtained by lumbar puncture from subjects with signs and symptoms of meningitis and/or encephalitis following completion of routine testing Specimen that have not undergone more than 3 freeze/thaw cycles.
Exclusion Criteria:
- Specimens not fitting criteria outlined above.
- CSF obtained from an external ventricular drain or shunt source.
- Lack of clear subject identification or label on residual banked CSF specimen.
- Specimen has been centrifuged.
- Obvious physical damage of banked residual specimen.
- Repeat specimens from the same subject.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PPA
Time Frame: 6 months
|
positive percentage agreement
|
6 months
|
NPA
Time Frame: 6 months
|
negative percentage agreement
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Sarah Johnson, QIAGEN Gaithersburg, Inc
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 6, 2022
Primary Completion (Estimated)
December 31, 2023
Study Completion (Estimated)
March 31, 2024
Study Registration Dates
First Submitted
December 9, 2021
First Submitted That Met QC Criteria
December 9, 2021
First Posted (Actual)
December 13, 2021
Study Record Updates
Last Update Posted (Estimated)
June 19, 2023
Last Update Submitted That Met QC Criteria
June 16, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMF-DHF-18-0489-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
all samples are residual and anonymized
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Meningitis/Encephalitis
-
QIAGEN Gaithersburg, IncCompletedMeningitis/EncephalitisUnited Kingdom
-
Shanghai Children's Medical CenterBioMérieuxUnknownMeningitis/Encephalitis
-
University Hospital, Basel, SwitzerlandRecruitingAdult Patients With Suspected Meningitis and/or EncephalitisSwitzerland
-
Assistance Publique Hopitaux De MarseilleUnknownMeningo-encephalitis | Community-based MeningitisFrance
-
Vinmec Research Institute of Stem Cell and Gene...CompletedEncephalitis | MeningitisVietnam
-
NovartisNovartis VaccinesCompletedJapanese Encephalitis | Rabies | Yellow Fever | Meningococcal Disease | Typhoid | Meningococcal MeningitisCzech Republic, Germany
-
D'Or Institute for Research and EducationCenters for Disease Control and Prevention; Oswaldo Cruz FoundationCompletedEncephalitis | Meningitis | Prognosis | Intensive Care Neurological Disorder | Meningitis/Encephalitis | Central Nervous System Infections and InflammationsBrazil
-
Xijing HospitalUnknownStroke | Vertigo | Headache | Meningitis/Encephalitis
-
Institute of Tropical Medicine, BelgiumUniversiteit Antwerpen; Victor Babes Hospital, Bucharest, RomaniaWithdrawnOxidative Stress | West Nile Virus | West Nile Fever | West Nile Fever Encephalitis | West Nile Fever Meningitis | West Nile Meningitis | West Nile Virus Meningoencephalitis | West Nile Fever Meningoencephalitis | West Nile Fever With Neurologic ManifestationRomania
-
Oxford University Clinical Research Unit, VietnamUniversity of Rochester; University of Liverpool; Liverpool School of Tropical... and other collaboratorsCompletedHiv | Meningitis | Meningoencephalitis | Meningitis StreptococcalVietnam
Clinical Trials on QIAstat-Dx® Meningitis/Encephalitis (ME) Panel
-
Shanghai Children's Medical CenterBioMérieuxUnknownMeningitis/Encephalitis
-
QIAGEN Gaithersburg, IncCompletedRespiratory DiseaseUnited Kingdom
-
QIAGEN Gaithersburg, IncNot yet recruiting
-
Karolinska InstitutetMbarara University of Science and Technology; Science for Life Laboratory; Epicentre... and other collaboratorsCompleted